Growth hormone co-treatment for ovulation induction may enhance conception in the co-treatment and succeeding cycles, in clonidine negative but not clonidine positive patients.

Plain-language guide to PMID 8027274 (1994): crossover randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin) in 24 patients.

Key Facts

PMID: 8027274
Journal: Human reproduction (Oxford, England)
Year: 1994
Study type: Randomized Controlled Trial
Authors: Blumenfeld Z et al. (4 authors)
DOI: 10.1093/oxfordjournals.humrep.a138483

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin), published as a randomized controlled trial.

To investigate the effect of co-treatment with growth hormone (GH) for ovulation induction with human menopausal gonadotrophins (HMG) on conception, the researchers compared the pregnancy rate and response to co-treatment with GH versus HMG/human chorionic gonadotrophin (HCG) alone in a prospective, randomized, cross-over protocol of ovulation induction for either in-vivo or in-vitro fertilization (IVF).

Why It Was Studied

The main outcome measures were the amount of gonadotrophin used and conception.

Who Took Part

The study group was 24 patients.

The age groups tagged for this paper are adults, women only.

How the Study Was Run

The design is described as randomized and crossover.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

In the crossover set-up each of the patients took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

What Was Measured

The main outcome measures were the amount of gonadotrophin used and conception.

PubMed files the paper under topics including Chorionic Gonadotropin, Clonidine, Growth Hormone, Menotropins, Menstrual Cycle, Ovulation Induction and Predictive Value of Tests.

What This Means in Plain Language

The paper is a randomized and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin) in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1994 (Human reproduction (Oxford, England)), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the hCG (human chorionic gonadotropin) compound page, all human trials.

Our Notes on the Compounds

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

hCG (human chorionic gonadotropin): An LH analog that drives Leydig-cell testosterone production.

HMG (Human Menopausal Gonadotropin): Menotropins: a glycoprotein preparation that supplies follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.